ImmunoGen

• Companies Invest in Antibodies That Fight Tumors

  By Eileen Rojas - May 13, 2013 | Tickers: IMGN, RHHBY, SGEN

  In the war against cancer, a new weapon holds promise to treat the disease in a novel way. ADCs, or antibody drug conjugates, use antibodies linked to potent anti-cancer therapeutic agents that deliver a better way of killing cancerous cells while minimizing side effects for patients. Clinical trials currently underway have so far shown very promising results.

  How do ADCs work?

  According to Dr. Marco Timmers, CSO at Synthon Biopharmaceuticals more »

• This Biotech Stock Looks Like a Good Investment

  By Terry Chrisomalis - April 6, 2013 | Tickers: IMGN, MRK, SGEN

  The biotech sector is heating up with new technology platforms that are showing big promise. One such big promising technology comes from a company known as ImmunoGen (NASDAQ: IMGN). ImmunoGen uses a system called the "TAP" technology, also known as Targeted Antibody Payload.  

  Currently, antibodies are able to bind to cancer cells but have no effect on killing the target cancer cells. This is where ImmunoGen's technology comes into more »

• Is It The Right Time For Immunogen?

  By Terry Chrisomalis - April 3, 2013 | Tickers: IMGN, MRK, SGEN

  The biotech sector is heating up with new technology platforms that are showing big promise. One such big promising technology comes from a company known as Immunogen (NASDAQ: IMGN). Immunogen uses a system called the "TAP" technology, also known as Targeted Antibody Payload.  Currently antibodies are able to bind to cancer cells but have no effect on killing the target cancer cells. This is where Immunogen's technology comes into more »

• Heroic, But Profitable For Investors?

  By Bill Edson - January 18, 2013 | Tickers: ECYT, IMGN, INCY, NVS, SNY

  Editor's Note: The original article had the market capitalization incorrect for Senesco Technologies and Lorus Therapeutics. This version has been corrected and Motley Fool apologizes for the error.
  

  Companies like Incyte (NASDAQ: INCY), Immunogen (NASDAQ: IMGN), Endocyte (NASDAQ: ECYT) and Senesco Technologies are putting their research efforts towards the eradication and control of cancers. Though their efforts are often ingenious and heroic, that does not necessarily make them recommendable more »

• Roche Leads Pack for Upcoming FDA Approvals

  By Tedra DeSue - January 7, 2013 | Tickers: AVEO, DCTH, IMGN, RHHBY

  Several drugs that could be used to treat cancer patients are slated for approval by the U.S. Food and Drug Administration (FDA) during the first half of the year. Some of the manufacturers of these treatments are touting the medicines as being the next break through in treating the various forms of the deadly disease. This gives them the chance to continue to expand their presence in the multi-billion more »

• Spectrum Pharmaceuticals: It's Do or Die Before Earnings

  By Brian Nichols - October 29, 2012 | Tickers: DNDN, IMGN, QCOR, SPPI

  Spectrum Pharmaceuticals (NASDAQ: SPPI) may be looking to repeat a bit of history that I’m sure it wishes to avoid -- between November 2009 and November 2010, the stock traded with a modest loss; if SPPI does not begin to trade with an aggressive uptrend, it could experience the same fate. With earnings on Wednesday, it’s do or die for Spectrum Pharmaceuticals’ short-term trend.

  The company will announce earnings more »

• Pinktober Biotechs

  By AnnaLisa Kraft - October 13, 2012 | Tickers: CELG, GALE, IMGN

  Pinktober is here and all things breast cancer awareness related. If you are a breast cancer survivor I understand it can be painful to be reminded at every turn but just remember it means progress for the women after you. If you know at least eight females, one will likely be diagnosed with breast cancer in her lifetime. And there are some biotechs making advances in the field, Celgene (NASDAQ: CELGmore »)

• Six Disruptive Biotech Stocks

  By Streetwise Reports - August 18, 2012 | Tickers: AVEO, DNDN, IMGN, SGEN, VRTX

  By George S. Mack, The Life Sciences Report

   For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

   

  Imagine a novel discovery or even a novel platform that just fizzles. To a technology freak like me that sounds so disappointing to think that you can actually discover breakthrough ideas that are not disruptive and don't really change much. I recently spoke more »

• Exclusive: Five Biotechs Picks from a Top Biotechnology Analyst

  By Streetwise Reports - August 3, 2012 | Tickers: CELG, CLDX, IMGN, NLNK, ONTY

  Five biotechs to consider

  By George S. Mack, The Life Sciences Report

  For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

  Immunity is cancer's enemy

  The complexity of the mammalian immune system is daunting for molecular biologists and drug developers, but incremental progress has brought biotech and biopharma to the point where small molecules and biologics are being developed with more »